Kang Jiuhong, Chen Jie, Shi Yufeng, Jia Jie, Zhang Yuntao
School of Life Sciences, Institute of Physics, Lanzou University, Lanzou 730000, China.
Biochem Pharmacol. 2005 Apr 15;69(8):1205-13. doi: 10.1016/j.bcp.2005.01.014.
Curcumin (Cur), a well-known dietary pigment derived from Curcuma longa, is a promising anticancer drug, but its in vivo target molecules remain to be clarified. Here we report that exposure of human hepatoma cells to Cur led to a significant decrease of histone acetylation. Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are the enzymes controlling the state of histone acetylation in vivo. Cur treatment resulted in a comparable inhibition of histone acetylation in the absence or presence of trichostatin A (the specific HDAC inhibitor), and showed no effect on the in vitro activity of HDAC. In contrast, the domain negative of p300 (a most potent HAT protein) could block the inhibition of Cur on histone acetylation; and the Cur treatment significantly inhibited the HAT activity both in vivo and in vitro. Thus, it is HAT, but not HDAC that is involved in Cur-induced histone hypoacetylation. At the same time, exposure of cells to low or high concentrations of Cur diminished or enhanced the ROS generation, respectively. And the promotion of ROS was obviously involved in Cur-induced histone hypoacetylation, since Cur-caused histone acetylation and HAT activity decrease could be markedly diminished by the antioxidant enzymes, superoxide dismutase (SOD), catalase (CAT) or their combination, but not by their heat-inactivated forms. The data presented here prove that HAT is one of the in vivo target molecules of Cur; through inhibiting its activity, Cur induces histone hypoacetylation in vivo, where the ROS generation plays an important role. Considering the critical roles of histone acetylation in eukaryotic gene transcription and the involvement of histone hypoacetylation in the lose of cell viability caused by high concentrations of Cur, these results open a new door for us to further understand the molecular mechanism involved in the in vivo function of Cur.
姜黄素(Cur)是一种从姜黄中提取的著名食用色素,是一种很有前景的抗癌药物,但其体内靶分子仍有待阐明。在此我们报告,将人肝癌细胞暴露于姜黄素会导致组蛋白乙酰化显著降低。组蛋白乙酰转移酶(HAT)和组蛋白去乙酰化酶(HDAC)是在体内控制组蛋白乙酰化状态的酶。在存在或不存在曲古抑菌素A(特异性HDAC抑制剂)的情况下,姜黄素处理对组蛋白乙酰化的抑制作用相当,并且对HDAC的体外活性没有影响。相反,p300(一种最有效的HAT蛋白)的结构域阴性可以阻断姜黄素对组蛋白乙酰化的抑制作用;并且姜黄素处理在体内和体外均显著抑制HAT活性。因此,参与姜黄素诱导的组蛋白低乙酰化的是HAT,而非HDAC。同时,将细胞暴露于低浓度或高浓度的姜黄素分别会减少或增加活性氧(ROS)的产生。并且ROS的增加显然参与了姜黄素诱导的组蛋白低乙酰化,因为抗氧化酶超氧化物歧化酶(SOD)、过氧化氢酶(CAT)或它们的组合可显著减少姜黄素引起的组蛋白乙酰化和HAT活性降低,而热灭活形式的抗氧化酶则无此作用。此处提供的数据证明HAT是姜黄素的体内靶分子之一;通过抑制其活性,姜黄素在体内诱导组蛋白低乙酰化,其中ROS的产生起重要作用。鉴于组蛋白乙酰化在真核基因转录中的关键作用以及组蛋白低乙酰化参与高浓度姜黄素导致的细胞活力丧失,这些结果为我们进一步了解姜黄素体内功能所涉及的分子机制打开了一扇新的大门。